Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

227 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outcomes after 18 months of eliglustat therapy in treatment-naïve adults with Gaucher disease type 1: The phase 3 ENGAGE trial.
Mistry PK, Lukina E, Ben Turkia H, Shankar SP, Baris H, Ghosn M, Mehta A, Packman S, Pastores G, Petakov M, Assouline S, Balwani M, Danda S, Hadjiev E, Ortega A, Gaemers SJM, Tayag R, Peterschmitt MJ. Mistry PK, et al. Among authors: ghosn m. Am J Hematol. 2017 Nov;92(11):1170-1176. doi: 10.1002/ajh.24877. Epub 2017 Oct 3. Am J Hematol. 2017. PMID: 28762527 Free PMC article. Clinical Trial.
Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial.
Mistry PK, Lukina E, Ben Turkia H, Amato D, Baris H, Dasouki M, Ghosn M, Mehta A, Packman S, Pastores G, Petakov M, Assouline S, Balwani M, Danda S, Hadjiev E, Ortega A, Shankar S, Solano MH, Ross L, Angell J, Peterschmitt MJ. Mistry PK, et al. Among authors: ghosn m. JAMA. 2015 Feb 17;313(7):695-706. doi: 10.1001/jama.2015.459. JAMA. 2015. PMID: 25688781 Free PMC article. Clinical Trial.
Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final results.
Mistry PK, Lukina E, Ben Turkia H, Shankar SP, Baris Feldman H, Ghosn M, Mehta A, Packman S, Lau H, Petakov M, Assouline S, Balwani M, Danda S, Hadjiev E, Ortega A, Foster MC, Gaemers SJM, Peterschmitt MJ. Mistry PK, et al. Among authors: ghosn m. Am J Hematol. 2021 Sep 1;96(9):1156-1165. doi: 10.1002/ajh.26276. Epub 2021 Jul 11. Am J Hematol. 2021. PMID: 34161616 Free PMC article. Clinical Trial.
The Therapeutic use of human albumin in cancer patients' management.
Moujaess E, Fakhoury M, Assi T, Elias H, El Karak F, Ghosn M, Kattan J. Moujaess E, et al. Among authors: ghosn m. Crit Rev Oncol Hematol. 2017 Dec;120:203-209. doi: 10.1016/j.critrevonc.2017.11.008. Epub 2017 Nov 20. Crit Rev Oncol Hematol. 2017. PMID: 29198333 Review.
Treatment of cancer patients in their last month of life: aimless chemotherapy.
Assi T, El Rassy E, Tabchi S, Ibrahim T, Moussa T, Chebib R, El Karak F, Farhat F, Chahine G, Nasr F, Ghosn M, Kattan J. Assi T, et al. Among authors: ghosn m. Support Care Cancer. 2016 Apr;24(4):1603-8. doi: 10.1007/s00520-015-2959-3. Epub 2015 Sep 21. Support Care Cancer. 2016. PMID: 26391890
Lung cancer and immunotherapy: a real-life experience from second line and beyond.
El Karak F, Gh Haddad F, Eid R, Al Ghor M, El Rassy E, Ahmadieh N, Choullamy T, Halim NA, Tfayli A, Farhat F, Kattan J, Nasr F, Ghosn M, Assi HI. El Karak F, et al. Among authors: ghosn m. Future Oncol. 2019 Sep;15(26):3025-3032. doi: 10.2217/fon-2019-0144. Epub 2019 Aug 19. Future Oncol. 2019. PMID: 31424958
227 results